Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Natural Signals and Ambient Dendritic Cells to Culture-Expand Cancer Targeting T-Cells Directly From Unfractionated Peripheral Blood: A Phase 1 T-Cell Dose Escalation Trial Targeting Relapsed and Refractory MUC1-Expressing Multiple Myeloma

NCT05411497 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05411497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05411497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Natural Signals and Ambient Dendritic Cells to Culture-Expand Cancer Targeting T-Cells Directly From Unfractionated Peripheral Blood: A Phase 1 T-Cell Dose Escalation Trial Targeting Relapsed and Refractory MUC1-Expressing Multiple Myeloma
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 20, 2022
Completion date
August 18, 2027
Enrollment
5 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent plasma cell myeloma, refractory plasma cell myeloma